/* Style Definitions */ table.MsoNormalTable {mso-style-name:"Table Normal"; mso-tstyle-rowband-size:0; mso-tstyle-colband-size:0; mso-style-noshow:yes; mso-style-priority:99; mso-style-parent:""; mso-padding-alt:0in 5.4pt 0in 5.4pt; mso-para-margin:0in; mso-para-margin-bottom:.0001pt; mso-pagination:widow-orphan; font-size:10.0pt; font-family:"Times New Roman","serif";}

Pieter obtained an MSc degree in biomedical sciences from Utrecht University, and a PhD degree in pharmacology from Leiden University at the lab of Prof. Douwe Breimer. He is an award-winning researcher who published in several high-ranking journals. Pieter pioneered the development of a Blood-Brain Barrier model in tissue-cultured cells. Based on his unique know-how, he founded to-BBB in 2003. With his team, he successfully raised five rounds of investments – from seed capital to Series B – to build and grow the company. In 2008, he licensed the G-Technology® from Taiwanese research institute ITRI as the company’s new proprietary brain delivery platform. He effectively led the company through discovery and preclinical phases of drug development, delivering lead product 2B3-101 in a clinical phase I/II trial in 2011. His decades of knowledge on brain diseases and experience with various pre-clinical models will guarantee successful project management and completion by industry standards.